Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dapsone
Drug ID BADD_D00580
Description A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
Indications and Usage For the treatment and management of leprosy and dermatitis herpetiformis.
Marketing Status approved; investigational
ATC Code D10AX05; J04BA02
DrugBank ID DB00250
KEGG ID D00592
MeSH ID D003622
PubChem ID 2955
TTD Drug ID D0MA9N
NDC Product Code 0023-5206; 29967-0007; 16110-526; 49938-102; 51672-4197; 68308-342; 51927-0085; 53596-014; 13668-605; 70954-135; 0713-0886; 16714-956; 51552-1042; 29033-036; 49938-101; 60429-495; 0378-4830; 14474-038; 50218-008; 51927-0083; 73309-094; 51672-1387; 71052-100; 72375-0006; 16110-367; 29033-037; 43353-222; 51672-1388; 60429-496; 60758-670; 70954-136; 10695-047; 51927-0084; 51672-4198; 46438-0645; 49452-2439; 65571-0021; 76072-1018; 64980-566; 14474-026; 45562-1120; 51927-4368; 58159-033; 43353-223; 0023-3670
UNII 8W5C518302
Synonyms Dapsone | DADPS | Sulfonyldianiline | Diaminodiphenylsulfone | Diaphenylsulfone | 4,4'-Diaminophenyl Sulfone | 4,4' Diaminophenyl Sulfone | Sulfone, 4,4'-Diaminophenyl | Sulfona | Dapson-Fatol | Disulone | Avlosulfone | Dapsoderm-X
Chemical Information
Molecular Formula C12H12N2O2S
CAS Registry Number 80-08-0
SMILES C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urticaria23.04.02.001; 10.01.06.0010.004473%
Ventricular arrhythmia02.03.04.0060.000550%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.0030.003007%
Mental status changes19.07.01.0010.000550%Not Available
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.0050.000367%Not Available
Application site dryness08.02.01.011; 23.03.03.024; 12.07.01.0110.002493%Not Available
Lupus-like syndrome10.04.03.003; 23.03.02.004; 15.06.02.004--Not Available
Tonic clonic movements17.12.03.006--Not Available
Nerve injury17.02.10.007; 12.01.12.002--Not Available
Protein urine present13.13.02.006--Not Available
Type IV hypersensitivity reaction10.01.03.0220.000367%Not Available
Nodule08.03.05.0020.000367%Not Available
Vanishing bile duct syndrome09.02.03.0030.001467%Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.004363%Not Available
Application site discolouration23.03.03.023; 12.07.01.030; 08.02.01.0300.002493%Not Available
Red blood cell abnormality01.07.02.006--Not Available
Blood disorder01.05.01.0040.000807%Not Available
Psychotic disorder19.03.01.002--
Carditis02.11.03.0010.000367%Not Available
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.000367%Not Available
Application site burn23.03.11.013; 12.07.01.038; 08.02.01.038--Not Available
Bone marrow failure01.03.03.0050.000550%
Treatment failure08.06.01.0170.000367%Not Available
Liver injury12.01.17.012; 09.01.07.0220.000733%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000367%
Acute kidney injury20.01.03.0160.002933%
Drug-induced liver injury09.01.07.023; 12.03.01.0440.009350%Not Available
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.027682%Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene